Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response

19 Dec 2020

Abstract excerpt

Theranostics are emerging as a pillar of cancer therapy that enable the use of single molecule constructs for diagnostic and therapeutic application. As poly adenosine diphosphate (ADP)-ribose polymerase 1 (PARP-1) is overexpressed in various cancer types, and is localized to the nucleus, PARP-1 can be safely targeted with Auger emitters to induce DNA damage in tumors. Here, we investigated a radioiodinated PARP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Integrated Circuits and Semiconductor Failure Analysis
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to PARP inhibition in cancer therapy

Source

Identifiers

PMID: 33352773
DOI: 10.3390/molecules25246029

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor ResponsePMID 33352773Read ↗

PARP-1–Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human NeuroblastomaSemantic proximity Read ↗

Advancements in PARP1 Targeted Nuclear Imaging and Theranostic ProbesSemantic proximity Read ↗

DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and RadiotherapySemantic proximity Read ↗

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation TherapySemantic proximity Read ↗

A PET imaging agent for evaluating PARP-1 expression in ovarian cancerSemantic proximity Read ↗

A Radiotracer Strategy to Quantify PARP-1 Expression <i>In Vivo</i> Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor TherapySemantic proximity Read ↗

Molecular Imaging of PARPSemantic proximity Read ↗

Single cell resolution in vivo imaging of DNA damage following PARP inhibition.Semantic proximity Read ↗

Molecular Imaging: PARP-1 and BeyondSemantic proximity Read ↗

Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical ModelsSemantic proximity Read ↗

In vivo visualization of PARP inhibitor pharmacodynamicsSemantic proximity Read ↗

PARP inhibition radiosensitizes BRCA1 wildtype and mutated breast cancer to proton therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.